Charting the Etanercept Journey: Tracing Cost Dynamics in Poland’s Off-Patent Market from Reference Drug Rivalry to Biosimilar Monopoly-Reference-Cited by-同舟云学术

Charting the Etanercept Journey: Tracing Cost Dynamics in Poland’s Off-Patent Market from Reference Drug Rivalry to Biosimilar Monopoly

Published:2024-06-11 Issue:4 Volume:38 Page:557-569
ISSN:1173-8804
Container-title:BioDrugs
language:en
Short-container-title:BioDrugs

Author:

Stajszczyk Marcin^ORCID,Batko Krzysztof^ORCID,Żuber Zbigniew Michał^ORCID,Kwiatkowska Brygida^ORCID,Krajewska-Włodarczyk Magdalena^ORCID,Batko Bogdan^ORCID

Funder

Polish Society for Rheumatology

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40259-024-00663-4.pdf

Reference42 articles.

1. Burmester GR, Bijlsma JWJ, Cutolo M, McInnes IB. Managing rheumatic and musculoskeletal diseases—past, present and future. Nat Rev Rheumatol. 2017;13(7):443–8. https://doi.org/10.1038/nrrheum.2017.95.

2. Kerrigan SA, McInnes IB. Reflections on “older” drugs: learning new lessons in rheumatology. Nat Rev Rheumatol. 2020;16(3):179–83. https://doi.org/10.1038/s41584-020-0375-7.

3. Landgren E, Bremander A, Lindqvist E, Nylander M, Larsson I. Patients’ perceptions of person-centered care in early rheumatoid arthritis: a qualitative study. ACR Open Rheumatol. 2021;3(11):788–95. https://doi.org/10.1002/acr2.11326.

4. Putrik P, Ramiro S, Kvien TK, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014;73:198–206.

5. Stajszczyk M, Obarska I, Jeka S, Batko B. Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database. Ann Rheum Dis. 2023;82(9):1171–80. https://doi.org/10.1136/ard-2022-223696.